News
BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients
Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial.